AI주식인사이트AI Stock Insight
A

엔젠바이오

354200KOSDAQ그외 기타 전문, 과학 및 기술 서비스업

72.1 / 100

Reference Date: 2026-07-24

Financial Score20.0 / 40
News Sentiment19.1 / 25
Momentum18.0 / 20
Disclosure15.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Surged 170.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

EnzenBio is a biotech company specializing in in vitro diagnostic medical devices and services using genomic analysis, liquid biopsy, and precision diagnostics. It leverages next-generation sequencing (NGS) and bioinformatics algorithms to detect mutations in cancer and genetic diseases, offering personalized treatment solutions.

Number of Employees

56people

Average Salary

61.8M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 42.304.0Point
PBR
0.79Industry Average 1.085.5Point

Lower than industry avg (good)

ROE
-33.54Industry Average 0.940.0Point

Well below industry avg

Debt Ratio
7.51Industry Average 12.515.0Point

Lower than industry avg (good)

Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲152.0% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲14.4% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -59.2% (improving, 3yr)

Detailed News Sentiment

8 totalPositive 6Neutral 2Negative 0Average Sentiment Score 76.2

Detailed Momentum

52-week position6.0Point

52w upper range (66%)

Current 1,990Won52-week high 2,63552-week low 737
1-month return6.0Point

1m +170.01% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

17 totalPositive 5Neutral 12Negative 0
  • Neutral[발행조건확정]증권신고서(지분증권)2026-07-20
  • Neutral효력발생안내( 2026.7.2. 제출 증권신고서(지분증권) )2026-07-20
  • Positive권리락 (유상증자)2026-07-20
  • Positive유상증자1차발행가액결정2026-07-20
  • Neutral투자설명서2026-07-20